Clearmind Medicine and Yissum File Patent for New Psychedelic PTSD Treatment

Clearmind Medicine Inc., a clinical-stage biotech company headquartered in Vancouver, Canada, has announced the submission of a patent application under the International Patent Cooperation Treaty (PCT). This action is the result of an ongoing collaboration with Yissum Research Development Company of the Hebrew University of Jerusalem. Clearmind holds an exclusive licensing agreement with Yissum, enabling the two entities to work together in developing novel psychedelic-derived therapeutics aimed at addressing significant unmet medical needs.

The patent application focuses on innovative compounds created by Professors Rami Yaka, Ahmed Masaewa, and Avi Priel of the Hebrew University. These compounds are primarily designed to treat post-traumatic stress disorder (PTSD) and other mental health conditions. The global market for PTSD treatment, valued at $16.8 billion in 2023, is projected to grow to $27.37 billion by 2033, according to Future Market Insights. PTSD is a psychiatric disorder characterized by a significant lack of effective treatment options, leaving a substantial gap in patient care.

Currently, the management of PTSD involves a combination of patient education, social support, psychotherapy, and psychopharmacological interventions. However, these methods often have limited efficacy and are associated with various side effects such as nausea, weight gain, sexual dysfunction, insomnia, and increased anxiety. This highlights the urgent need for new and more effective treatments.

Clearmind's CEO, Dr. Adi Zuloff-Shani, expressed pride in the collaboration with Yissum, noting the groundbreaking innovations they are developing together. The goal is to provide advanced treatments for various mental health conditions, particularly PTSD, where moderate to severe cases have very limited pharmacological options. The only two FDA-approved drugs for PTSD often come with significant side effects, emphasizing the need for safer and more effective alternatives. Dr. Zuloff-Shani stated that Clearmind aims to deliver next-generation psychedelic compounds that could significantly improve the quality of life for PTSD patients.

Clearmind Medicine Inc. is dedicated to the discovery and development of novel psychedelic-derived therapeutics to address widespread and underserved health problems, including alcohol use disorder. The company's primary mission is to research and develop psychedelic-based compounds and commercialize them as regulated medicines, foods, or supplements. Clearmind's intellectual property portfolio currently includes nineteen patent families with 29 granted patents. The company is also committed to seeking additional patents for its compounds whenever appropriate and remains open to acquiring more intellectual property to expand its portfolio.

Yissum, the technology transfer company of the Hebrew University of Jerusalem, was founded in 1964 and serves as a bridge between cutting-edge academic research and the global community of entrepreneurs, investors, and industry. Yissum aims to benefit society by converting innovative academic research into practical commercial solutions. To date, the company has registered over 11,680 patents globally, licensed more than 1,160 technologies, and spun out over 260 companies. Yissum's business partners span the globe, reflecting its extensive reach and impact.

In summary, Clearmind Medicine Inc.'s latest patent application represents a significant step forward in the development of new treatments for PTSD and other mental health conditions. The collaboration with Yissum is yielding promising results, with the potential to offer safer and more effective therapeutic options for patients suffering from these debilitating disorders.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!